James Hambro & Partners LLP Makes New Investment in Insulet Co. (NASDAQ:PODD)

James Hambro & Partners LLP purchased a new position in shares of Insulet Co. (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 915 shares of the medical instruments supplier’s stock, valued at approximately $213,000.

Several other institutional investors also recently modified their holdings of PODD. Revolve Wealth Partners LLC acquired a new position in Insulet during the third quarter valued at approximately $368,000. Chicago Capital LLC boosted its holdings in shares of Insulet by 3.4% in the third quarter. Chicago Capital LLC now owns 168,434 shares of the medical instruments supplier’s stock valued at $39,203,000 after buying an additional 5,557 shares during the period. Raymond James & Associates boosted its holdings in shares of Insulet by 3.8% in the third quarter. Raymond James & Associates now owns 37,456 shares of the medical instruments supplier’s stock valued at $8,718,000 after buying an additional 1,367 shares during the period. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in shares of Insulet by 3.0% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,453 shares of the medical instruments supplier’s stock valued at $1,502,000 after buying an additional 188 shares during the period.

Insulet Stock Performance

NASDAQ PODD traded down $0.73 on Monday, hitting $235.86. 118,374 shares of the stock were exchanged, compared to its average volume of 794,159. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. The business’s fifty day moving average is $218.20 and its 200 day moving average is $197.05. Insulet Co. has a 52 week low of $128.68 and a 52 week high of $243.98. The company has a market capitalization of $16.54 billion, a PE ratio of 43.02, a P/E/G ratio of 4.35 and a beta of 1.21.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.56 by ($0.01). The firm had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the company posted $0.38 earnings per share. Research analysts anticipate that Insulet Co. will post 3.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a report on Monday, October 14th. Raymond James upped their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Barclays upped their price target on shares of Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Citigroup boosted their price objective on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $242.29.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.